W. Nian

OA15.02 Phase 1 Studies of DZD9008, an Oral Selective EGFR/HER2 Inhibitor in Advanced NSCLC with EGFR Exon20 Insertion Mutations

P. Janne, D. Camidge, M. Millward, 2021, Journal of Thoracic Oncology.